Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards?
<b/> Gastroesophageal adenocarcinoma (GEA) comprises a myriad of distinct subtypes with significant interpatient, intrapatient, and intratumor heterogeneity. Strategies for tackling molecular heterogeneity will be essential for the success of GEA precision oncology-in this regard, blood-based "liquid biopsies" may provide broader views of the real-time genomic landscape of this disease, identifying actionable biomarkers and monitoring therapy resistance. Cancer Discov; 8(1); 14-6. ©2018 AACRSee related article by Pectasides et al., p. 37See related article by Janjigian et al., p. 49.